Announcements Trials
Browse Landscape

Status

Active not recruiting 3Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 15Observational 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 3Non-Small Cell Lung Cancer ALK-positive 1Lung Neoplasms 1

Interventions

Blood Specimen Collection 135Surveys and Questionnaires 132Specimen Handling 57Observation 55Radiotherapy 43Interviews as Topic 35Surgical Procedures, Operative 31Biopsy 30Drug Therapy 30Data Collection 25Magnetic Resonance Spectroscopy 25Nivolumab 21Immune Checkpoint Inhibitors 18Watchful Waiting 18Standard of Care 17Therapeutics 17Immunotherapy 16Magnetic Resonance Imaging 16trastuzumab deruxtecan 14Liquid Biopsy 13Restraint, Physical 13Tomography, X-Ray Computed 13palbociclib 13Radiosurgery 12enzalutamide 12Focus Groups 11Hematologic Tests 11apalutamide 11darolutamide 11pembrolizumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Observational × lorlatinib × 1 year × Clear all
NCT07556549 2026-05-22

A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC

Pfizer

Active not recruiting
50 enrolled
Thoracic

Non-Small Cell Lung Cancer ALK-positive

NCT07567352 2026-05-12

A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment

Pfizer

Active not recruiting
200 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06282991 2026-03-10

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

Pfizer

Completed
73 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06678555 2026-02-05

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.

Pfizer

Active not recruiting
35 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡